• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing

    9/4/24 5:51:17 PM ET
    $EBS
    $TROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $EBS alert in real time by email

    New York, New York, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oak Hill Advisors ("OHA") served as Administrative Agent and sole lender of a $250 million term loan facility supporting Emergent BioSolutions Inc. ("Emergent") (NYSE:EBS), a global company providing life-saving and life-extending products that address public health threats. The new debt financing will refinance Emergent's existing credit facility, reaching a significant step in its multi-year plan to stabilize its financial profile.

    In connection with the execution of the term loan, Emergent issued OHA 2.5 million warrants in addition to common stock with an aggregate value of $10 million. Both the number of shares and the warrant strike prices will be calculated based on the volume weighted average price per share for the 30 trading days ending on, but excluding, the 10th business day following the closing date.

    This bespoke term loan structure exemplifies OHA's strategic approach to partnering with companies to address complex and unique financial situations.

    "For the past 18 months, Emergent has executed on a series of actions to strengthen the balance sheet and streamline operations," said Joe Papa, president and CEO of Emergent. "These steps, which include finalizing several asset/site divestitures, resolving legacy issues, and now, securing this significant debt refinancing, are critical to stabilizing our financial profile."

    Papa continued, "We are thrilled to secure this new credit facility with Oak Hill Advisors as we are on track to reduce net debt by more than $200 million this year, positioning Emergent to enter its next phase of our turnaround, enabling future growth and additional investment opportunities with much greater freedom and flexibility to operate through favorable terms."

    Joseph Goldschmid, Managing Director at Oak Hill Advisors, added, "We are delighted to be a capital partner to Emergent. This financing provides the company with additional liquidity and flexibility to deliver on its business plan and continue to provide critical, life-saving products. We are excited to support and partner with the management team and company in this next chapter of growth."

    To access more information related to the new credit facility agreement, visit Emergent's recently filed Form 8-K and press release here.

    ###

    About OHA: Oak Hill Advisors (OHA) is a leading global credit-focused alternative asset manager with over 30 years of investment experience. OHA works with institutions and individuals and seeks to deliver a consistent track record of attractive risk-adjusted returns. The firm manages approximately $65 billion of capital across credit strategies, including private credit, high yield bonds, leveraged loans, stressed and distressed debt and collateralized loan obligations as of June 30, 2024. OHA's emphasis on long-term partnerships with companies, sponsors and other partners provides access to a proprietary opportunity set, allowing for customized credit solutions across market cycles.

    With over 400 experienced professionals across six global offices, OHA brings a collaborative approach to offering investors a single platform to meet their diverse credit needs. OHA is the private markets platform of T. Rowe Price Group, Inc. (NASDAQ – GS: TROW). For more information, please visit oakhilladvisors.com.



    Natalie Harvard, Head of Investor Relations & Partner
    Oak Hill Advisors, L.P.
    212-326-1505
    [email protected]
    
    Kristin Celestino, Public Relations
    Oak Hill Advisors, L.P.
    817-215-2934
    [email protected]
    
    Get the next $EBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EBS
    $TROW

    CompanyDatePrice TargetRatingAnalyst
    T. Rowe Price Group Inc.
    $TROW
    10/3/2025$108.00Market Perform
    BMO Capital Markets
    Emergent BioSolutions Inc.
    $EBS
    12/30/2024$15.00Buy
    H.C. Wainwright
    T. Rowe Price Group Inc.
    $TROW
    9/12/2024$109.00Equal Weight
    Wells Fargo
    T. Rowe Price Group Inc.
    $TROW
    8/27/2024$99.00Underweight
    Barclays
    Emergent BioSolutions Inc.
    $EBS
    8/22/2024$16.00Buy
    Rodman & Renshaw
    T. Rowe Price Group Inc.
    $TROW
    4/11/2024$106.00 → $120.00Underperform → Mkt Perform
    Keefe Bruyette
    T. Rowe Price Group Inc.
    $TROW
    4/8/2024$92.00 → $114.00Sell → Hold
    TD Cowen
    Emergent BioSolutions Inc.
    $EBS
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    More analyst ratings

    $EBS
    $TROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/15/25 4:02:40 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    $TROW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

    Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication  GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Nasal Spray product suite to include 6-count and 24-count multipack options, specifically designed to meet the needs of partners distributing higher volumes of naloxone. These new formats offer enhan

    2/12/26 6:00:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    /C O R R E C T I O N -- T. Rowe Price Group/

    In the news release, T. ROWE PRICE GROUP REPORTS MONTH-END ASSETS UNDER MANAGEMENT FOR JANUARY 2026, issued 11-Feb-2026 by T. Rowe Price Group over PR Newswire, the original version contained incorrect information introduced by PR Newswire during transmission. The complete, corrected release follows, with additional details at the end: T. ROWE PRICE GROUP REPORTS MONTH-END ASSETS UNDER MANAGEMENT FOR JANUARY 2026 BALTIMORE, Feb. 11, 2026 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced January month-end assets under management of $1.80 trillion. Net outflows for January 2026 were $5.2 billion.

    2/11/26 8:30:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $EBS
    $TROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel, Corp Sec Perl Jessica covered exercise/tax liability with 918 shares, decreasing direct ownership by 1% to 67,469 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:11:20 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Quality & Ethics, and CPL Glessner Coleen returned $315,009 worth of shares to the company (28,847 units at $10.92) and covered exercise/tax liability with 2,852 shares, decreasing direct ownership by 22% to 112,620 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:09:25 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Products Business Williams Paul Anthony returned $94,513 worth of shares to the company (8,655 units at $10.92) and covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 11% to 76,194 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:07:24 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    $TROW
    SEC Filings

    View All

    $EBS
    $TROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form SCHEDULE 13G filed by Emergent BioSolutions Inc.

    SCHEDULE 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    2/9/26 6:33:12 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    T. Rowe Price Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PRICE T ROWE GROUP INC (0001113169) (Filer)

    2/4/26 7:06:16 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Emergent BioSolutions Inc.

    SCHEDULE 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    1/30/26 1:31:10 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets initiated coverage on T. Rowe Price with a new price target

    BMO Capital Markets initiated coverage of T. Rowe Price with a rating of Market Perform and set a new price target of $108.00

    10/3/25 8:45:55 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

    H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

    12/30/24 7:24:57 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on T. Rowe Price with a new price target

    Wells Fargo initiated coverage of T. Rowe Price with a rating of Equal Weight and set a new price target of $109.00

    9/12/24 9:14:34 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $EBS
    $TROW
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    T. ROWE PRICE GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

    BALTIMORE, Feb. 4, 2026 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW), announced its financial results for the fourth quarter and full year 2025. The earnings release can be found on the firm's website at troweprice.com/newsroom. Chair, CEO, and President Rob Sharps and Chief Financial Officer Jen Dardis will provide an update on business performance, review financial results, and answer questions on a webcast today from 8:00 - 8:45 AM (Eastern Time). To access the webcast or to obtain dial-in instructions to ask a question, please visit investors.troweprice.com.

    2/4/26 7:00:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    T. ROWE PRICE GROUP REPORTS THIRD QUARTER 2025 RESULTS

    BALTIMORE, Oct. 31, 2025 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced its financial results for the third quarter of 2025. The earnings release can be found on the firm's website at troweprice.com/newsroom. Chair, Chief Executive Officer, and President Rob Sharps and Chief Financial Officer Jen Dardis will provide an update on business performance, review financial results, and answer questions on a webcast today from 8:00 - 8:45 AM ET. To access the webcast or to obtain dial-in instructions to ask a question, please visit investors.troweprice.com. Sup

    10/31/25 7:00:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $EBS
    $TROW
    Leadership Updates

    Live Leadership Updates

    View All

    STEPH JACKSON TO RETIRE FROM T. ROWE PRICE INVESTMENT MANAGEMENT

    Steven Krichbaum named successor and new head of TRPIM in 2027 BALTIMORE, Jan. 22, 2026 /PRNewswire/ -- T. Rowe Price announced today a planned leadership transition within its T. Rowe Price Investment Management division (TRPIM), as Steph Jackson, who currently serves as head of TRPIM and is a member of the Management Committee, will be retiring at the end of 2026. Jackson's tenure at T. Rowe Price has been marked by impactful leadership and a steadfast commitment to clients, associates, and community. Since joining T. Rowe Price in 2007, Jackson has held influential roles,

    1/22/26 8:45:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    T. ROWE PRICE ANNOUNCES CREATION OF GLOBAL STRATEGY FUNCTION

    BALTIMORE, Nov. 13, 2025 /PRNewswire/ -- T. Rowe Price announced today the creation of a Global Strategy function to drive its strategic vision and elevate long-term planning. Andrew Reich will join the firm as head of Global Strategy on January 5, 2026. In this role, Reich will oversee the firm's corporate strategy, corporate development, mergers and acquisitions, and product development. Reich brings deep industry expertise, having most recently served as a partner and head of the Asset Management Practice for North America at McKinsey & Company. During his tenure, he helped

    11/13/25 8:15:00 AM ET
    $TROW
    Investment Bankers/Brokers/Service
    Finance

    $EBS
    $TROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/8/24 5:23:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    9/10/24 12:09:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care